UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers

Thrombosis research, 2013-08, Vol.132 (2), p.180-184

2013

Volltextzugriff (PDF)

Hepatocellular Carcinoma: Special Issue Highlights

Cancers, 2020-07, Vol.12 (8), p.2026

2020

Volltextzugriff (PDF)

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells

Cancers, 2019-05, Vol.11 (5), p.681

2019

Volltextzugriff (PDF)

Updates in Biliary Tract Cancers

Cancers, 2022-06, Vol.14 (11), p.2746

2022

Volltextzugriff (PDF)

Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma

Journal of gastrointestinal oncology, 2023-10, Vol.14 (5), p.2192-2201

2023

Volltextzugriff (PDF)

A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer

American journal of clinical oncology, 2018-07, Vol.41 (7), p.649-655

2018

Volltextzugriff (PDF)

Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process

Cancers, 2020-09, Vol.12 (9), p.2375

2020

Volltextzugriff (PDF)

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

World journal of gastroenterology : WJG, 2015-02, Vol.21 (8), p.2450-2459

2015

Volltextzugriff (PDF)

A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study

Annals of surgical oncology, 2007-11, Vol.14 (11), p.3202-3209

2007

Volltextzugriff (PDF)

Renal Atrophy Secondary to Chemoradiotherapy of Abdominal Malignancies

International journal of radiation oncology, biology, physics, 2010-10, Vol.78 (2), p.539-546

2010

Volltextzugriff (PDF)

High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors

Anticancer research, 2009-10, Vol.29 (10), p.4127-4130

2009

Volltextzugriff (PDF)

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial

British journal of cancer, 2024-09

2024

Volltextzugriff (PDF)

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors

Cancer, 2020-08, Vol.126 (16), p.3689-3697

2020

Volltextzugriff (PDF)

Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Clinical cancer research, 2007-02, Vol.13 (3), p.965-971

2007

Volltextzugriff (PDF)

Akt expression may predict favorable prognosis in cholangiocarcinoma

Journal of gastroenterology and hepatology, 2006-11, Vol.21 (11), p.1744-1751

2006

Volltextzugriff (PDF)

Analysis of Clinical and Dosimetric Factors Associated With Change in Renal Function in Patients With Gastrointestinal Malignancies After Chemoradiation to the Abdomen

International journal of radiation oncology, biology, physics, 2010-03, Vol.76 (4), p.1193-1198

2010

Volltextzugriff (PDF)

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

Pharmacotherapy, 2014-02, Vol.34 (2), p.e9-e13

2014

Volltextzugriff (PDF)

Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report

Cancer chemotherapy and pharmacology, 2009-06, Vol.64 (1), p.177-181

2009

Volltextzugriff (PDF)

Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab

Pancreas, 2014-04, Vol.43 (3), p.343-349

2014

Volltextzugriff (PDF)

Impact of neuroendocrine tumor diagnosis (NET) on quality of life

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18614-e18614

2022

Volltextzugriff (PDF)

Immune cell molecular pharmacodynamics of lanreotide in relation to treatment response

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e16213-e16213

2022

Volltextzugriff (PDF)

Hepatocellular Carcinoma: Special Issue Highlights

Cancers, 2020-08, Vol.12 (8), p.1

2020

Volltextzugriff (PDF)

A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.472-472

2024

Volltextzugriff (PDF)

Agrin as a prognostic biomarker in hepatocellular carcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.559-559

2024

Volltextzugriff (PDF)

Genomic predictors of sensitivity to chemotherapy and immunotherapy in cholangiocarcinoma

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.540-540

2024

Volltextzugriff (PDF)

1 – 25 von 100

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(90)
Mit Volltextzugriff
(92)

Publikationsform

Sprache

Englisch
(100)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(23)
Science & Technology
(23)
Humans
(18)
Oncology
(17)
Female
(14)
Male
(13)
Middle Aged
(12)
Aged
(11)
Adult
(9)
Aged, 80 And Over
(8)
Tumors
(8)
Biological And Medical Sciences
(7)
Chemotherapy
(7)
Medical Sciences
(7)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(6)
Gemcitabine
(6)
Deoxycytidine - Analogs & Derivatives
(5)
Gastroenterology & Hepatology
(5)
Quality Of Life
(5)
Cholangiocarcinoma
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers

Hepatocellular Carcinoma: Special Issue Highlights

Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells

Updates in Biliary Tract Cancers

Evaluation of the serotonin pathway as a biomarker in cholangiocarcinoma

A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer

Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process

Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study

Renal Atrophy Secondary to Chemoradiotherapy of Abdominal Malignancies

High-dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors

TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors

Celecoxib and Mucosal Protection: Translation from an Animal Model to a Phase I Clinical Trial of Celecoxib, Irinotecan, and 5-Fluorouracil

Akt expression may predict favorable prognosis in cholangiocarcinoma

Analysis of Clinical and Dosimetric Factors Associated With Change in Renal Function in Patients With Gastrointestinal Malignancies After Chemoradiation to the Abdomen

Carboplatin Pharmacokinetics in a Patient Receiving Hemodialysis

Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report

Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab

Impact of neuroendocrine tumor diagnosis (NET) on quality of life

Immune cell molecular pharmacodynamics of lanreotide in relation to treatment response

Hepatocellular Carcinoma: Special Issue Highlights

A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer

Agrin as a prognostic biomarker in hepatocellular carcinoma

Genomic predictors of sensitivity to chemotherapy and immunotherapy in cholangiocarcinoma

Suchergebnisse filtern